Vitiligo — Clinical Policy Bulletin

Coverage Summary

Aetna Clinical Policy Bulletin (Number: 0422) addressing vitiligo defines which treatments, diagnostics, and CPT/HCPCS/ICD-10 codes are considered medically necessary, experimental/investigational, or cosmetic for management of vitiligo.

Coverage stance: mixed. This policy lists established medically necessary therapies (e.g., excimer laser, NB-UVB, PUVA, topical tacrolimus, corticosteroids) and numerous items considered experimental/investigational or cosmetic, and is intended to guide benefit administration rather than provide clinical advice.

Thresholds / Treatment timelines

Continued phototherapy follicular pigmentation requirementSignificant follicular pigmentation after 6 months of therapy (8 to 10 treatments per month)

Typical excimer laser treatments medically necessaryTreatments typically administered twice weekly and up to 60 treatments may generally be medically necessary

PUVA response timelineRepigmentation may begin after 15 to 25 PUVA treatments; response unlikely if follicular pigmentation has not appeared after 3 months of PUVA therapy

Medical-Necessity Criteria

Continued Phototherapy

Continued PUVA or NB-UVB therapy criteria

Continued Phototherapy: Continued PUVA or narrow-band UVB therapy is considered not medically necessary unless there is significant follicular pigmentation after 6 months of therapy (8 to 10 treatments per month).Significant follicular pigmentation after 6 months (approx. 48–60 treatments at 8–10/month)

Requires evidence of significant follicular pigmentation after 6 months (approx. 48–60 treatments at 8–10/month) to justify continuation

Not Medically Necessary / Experimental and Cosmetic

Aetna considers the items in the experimental and investigational list to be such because effectiveness has not been established. Examples named in the policy include home phototherapy, melanocyte transplantation (cultured and non-cultured), and tumor necrosis factor‑alpha agents (e.g., adalimumab, etanercept, infliximab), as well as other interventions such as apremilast, TNF‑alpha testing, and various surgical and unconventional therapies listed in the policy.

Coding

CPT codes covered if selection criteria are metCPTCovered

96900	Actinotherapy (ultraviolet light) [Narrow-band ultraviolet B (NB-UVB)]
96912	Photochemotherapy; psoralens and ultraviolet A (PUVA)
96913	Photochemotherapy (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least four to eight hours of care under direct supervision (includes application of medication and dressings)
96999	Unlisted special dermatological service or procedure [excimer laser]

CPT codes not covered for indications listed in the CPBCPTNot Covered

11920	Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin, including micropigmentation
11921	Tattooing additional code (as listed in source)
11922	Tattooing additional code (as listed in source)
15100	Split-thickness autograft, trunk, arms, legs; first 100 sq cm or less
15101	Each additional 100 sq cm or additional 1% body area
76376	3D rendering with interpretation and reporting of CT/MR/US or other tomographic modality with image postprocessing - not covered (3D/ image postprocessing)
76377	3D rendering requiring image postprocessing on an independent workstation - not covered
81291	MTHFR gene analysis (variants) - listed as not covered for vitiligo indications
97810	Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes [fire needle therapy]
97811	Acupuncture each additional 15 minutes [fire needle therapy]

1–10 of 15

1/2

HCPCS codes covered if selection criteria are metHCPCS|J-codesCovered

J0702	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
J1020	Injection, methylprednisolone acetate, 20 mg
J1030	Injection, methylprednisolone acetate, 40 mg
J1040	Injection, methylprednisolone acetate, 80 mg
J1094	Injection, dexamethasone acetate, 1 mg
J1100	Injection, dexamethasone sodium phosphate, 1 mg
J1700	Injection, hydrocortisone acetate, up to 25 mg
J1710	Injection, hydrocortisone sodium phosphate, up to 50 mg
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg
J2650	Injection, prednisolone acetate, up to 1 ml

1–10 of 19

1/2

A4633	Replacement bulb/lamp for ultraviolet light therapy system, each
E0691	Ultraviolet light therapy system panel, includes bulbs/lamps, timer, and eye protection; treatment area two square feet or less
E0692	Ultraviolet light therapy system panel, four foot panel
E0693	Ultraviolet light therapy system panel, six foot panel
E0694	Ultraviolet multidirectional light therapy system in 6 foot cabinet
J0135	Injection, adalimumab, 20 mg
J0636	Injection, calcitriol, 0.1 mcg
J1438	Injection, etanercept, 25 mg (Medicare administrative note)
J1745	Injection, infliximab, 10 mg
J2501	Injection, paricalcitol, 1 mcg

1–10 of 21

1/3

ICD-10 codes covered if selection criteria are metICD-10Covered

L80

Vitiligo

Provider Actions

Documentation Required

Document follicular pigmentation to continue phototherapy

To justify continued PUVA or NB-UVB beyond 6 months, provider must document significant follicular pigmentation after 6 months of therapy (8–10 treatments per month).

Billing Rule

Use unlisted CPT for excimer laser

Excimer laser is represented by CPT 96999 (unlisted dermatological procedure) when selection criteria are met.

96999
Excimer laser is represented by CPT 96999 (unlisted dermatological procedure) when selection criteria are met.

Background and Evidence

Vitiligo is an acquired pigmentary disorder characterized by expanding depigmented lesions; multiple pathogenic hypotheses are described including immune, neural, self‑destruct mechanisms and possible melanocyte growth factor deficiency or abnormal melatonin receptor involvement.

Treatments discussed in the policy include phototherapies (PUVA, narrow‑band UVB, excimer laser), topical agents (calcineurin inhibitors, corticosteroids), surgical approaches (melanocyte transplantation, suction blister/epidermal grafting, split‑thickness grafting), and a variety of experimental/unconventional interventions. Evidence summaries note that NB‑UVB is effective and compares favorably to PUVA, excimer laser has supportive small studies (up to 60 treatments commonly used), while evidence for many other interventions is mixed or limited and often based on small or low‑quality studies.

Study / Review	Key finding
NB-UVB vs PUVA (Yones et al 2007)	NB-UVB showed greater >50% BSA improvement (64% vs 36%) and better color match; superiority tended to be maintained at 12 months
Excimer laser studies	Multiple small studies report effectiveness in repigmentation; treatments typically twice weekly and up to 60 treatments may be medically necessary
Meta-analysis Dang et al 2016 (topical calcineurin inhibitors + phototherapy)	Combined calcineurin inhibitors with phototherapy showed better lesion outcomes vs placebo (lesion RR=2.62); caution re: photo-carcinogenesis
NB-UVB combination therapy network meta-analysis (Zhu 2023)	Several NB-UVB combinations ranked higher than NB-UVB monotherapy for ≥75% repigmentation (e.g., carboxytherapy, Er:YAG+5% 5-FU, needling)
Fire needle therapy systematic review (Luo 2020)	47 trials (3,618 patients): fire needle combined with conventional treatments showed higher efficacy (RR 1.55) but studies had poor methodology and were all from China
Apremilast + NB-UVB randomized study (Khemis 2020)	Apremilast + NB-UVB did not show benefit over placebo + NB-UVB for VASI at 24 weeks
Topical phenytoin gel (Abdou 2017)	Small study: limited responses (9/28) with non-significant immunohistochemical changes; further study recommended
MTHFR polymorphisms meta-analyses	Pooled analyses (5 studies) found no significant association between MTHFR C677T or A1298C and vitiligo risk
Intradermal mesotherapy NCTF135 pilot (Konstantinova 2019)	Pilot n=7: all patients had partial or complete repigmentation; no significant adverse events; requires controlled trials
OMP + NB-UVB retrospective study (Lee 2016)	n=32; 100% progression arrest within 12 weeks; 59.4% repigmentation >25%; limited by small size and short follow-up
Home-based phototherapy systematic review (Ashraf 2022)	3 studies (195 subjects): adherence better with home-based, adverse effects higher, effectiveness data insufficient
Topical prostaglandin analogs (latanoprost, bimatoprost)	Small RCT and case series show promising repigmentation when combined with NB-UVB; further research needed

Definitions

PUVA: Psoralen photochemotherapy (oral or topical psoralen followed by UVA exposure).

NB‑UVB: Narrow‑band ultraviolet B phototherapy (commonly administered 2–3 times weekly for several months).

Excimer laser: 308‑nm or Xenon‑Chloride excimer laser used to treat localized vitiligo.

OpenPayer